Stability of diluted iron polymaltose in PVC infusion bags

Journal of Pharmacy Practice and Research

Volumn 43, Issue 2, 2013, Pages 112-116

  Patel, Rahul P ^a   Wanandy, Troy ^b   Loring, Serena ^a   Johns, Cameron ^c   Hutchinson, Joseph ^c   Shastri, Madhur ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

^b ROYAL HOBART HOSPITAL   (Australia)

^c UNIVERSITY OF TASMANIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

IRON POLYMALTOSE; POLYVINYLCHLORIDE; SODIUM CHLORIDE;

ARTICLE; DRUG STABILITY; DRUG STORAGE; GEL PERMEATION CHROMATOGRAPHY; INFUSION SYSTEM; LIGHT; LIGHT SCATTERING; MOLECULAR WEIGHT; PARTICLE SIZE; PHYSICAL CHEMISTRY; REFRIGERATOR; ROOM TEMPERATURE;

EID: 84893386333     PISSN: 1445937X     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.2055-2335.2013.tb00232.x     Document Type: Article

References (29)

1. Goddard AF, James MW, McIntyre AS, Scott BB. Guidelines for the management of iron deficiency anaemia. Gut 2011; 60: 1309-16.
2. Bailie GR. Breaking new grounds in IV iron therapy. Eur J Hosp Pharm Pract 2008; 14: 25-7.
3. Gozzard D. When is high-dose intravenous iron repletion needed? Assessing new treatment options. Drug Des Devel Ther 2011; 5: 51-60.
4. Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs 2009; 69: 739-56.
5. Pasricha SR, Flecknoe-Brown SC, Allen KJ, Gibson PR, McMahon LP, Olynyk JK, et al. Diagnosis and management of iron deficiency anaemia: a clinical update. Med J Aust 2010; 193: 525-32.
6. Macdougall IC. Strategies for iron supplementation: oral versus intravenous. Kidney Int 1999; 69 (suppl): S61-S66.
7. Kumpf VJ. Update on parenteral iron therapy. Nutr Clin Pract 2003; 18: 318-26.
8. Geisser P, Burckhardt S. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics 2011; 3: 12-33.
9. Danielson BG. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol 2004; 15 (suppl): S93-S98.
10. Liu K, Kaffes AJ. Iron deficiency anaemia: a review of diagnosis, investigation and management. Eur J Gastroenterol Hepatol 2012; 24: 109-16.
11. Kudasheva DS, Lai J, Ulman A, Cowman MK. Structure of carbohydratebound polynuclear iron oxyhydroxide nanoparticles in parenteral formulations. J Inorg Biochem 2004; 98: 1757-69.
12. Singh K, Fong YF, Kuperan P. A comparison between intravenous iron polymaltose complex (Ferrum Hausmann) and oral ferrous fumarate in the treatment of iron deficiency anaemia in pregnancy. Eur J Haematol 1998; 60: 119-24.
13. Muñoz M, Gómez-Ramírez S, García-Erce JA. Intravenous iron in inflammatory bowel disease. World J Gastroenterol 2009; 15: 4666-74.
14. Van Wyck DB. Labile iron: manifestations and clinical implications. J Am Soc Nephrol 2004; 15 (suppl): S107-S111.
15. Geisser P, Baer M, Schaub E. Structure/histotoxicity relationship of parenteral iron preparations. Arzneimittelforschung 1992; 42: 1439-52.
16. Crichton RR, Danielson BG, Geisser P. Iron therapy with special emphasis on intravenous administration. 3rd ed. Bremen: Uni-Med Verlag AG; 2006. p.58-72.
17. Naim M, Hunter J. Intravenous iron replacement-management in general practice. Aust Fam Physician 2010; 39: 839-41.
18. Iron supplements (systemic). In: Bicopoulos D, Nooten AV, Bundy LA, et al. editors. AusDI advanced. St Leonards: Phoenix Medical Publishing Pty Ltd; 2012.
19. Iron polymaltose complex. In: Burridge N, editor. 4th ed. Australian injectable drug handbook. Collingwood: Society of Hospital Pharmacists of Australia; 2008. p.214-15
20. Ferrosig injection. In: eMIMs. June 2012 ed. St Leonards: UBM Medica Australia; 2012.
21. Garg M, Morrison G, Friedman A, Lau A, Lau D, Gibson PR. A rapid infusion protocol is safe for total dose iron polymaltose: time for change. Intern Med J 2011; 41: 548-54.
22. McClintock AD, Woods DJ, editors. Iron polymaltose. Wellington: New Zealand Hospital Pharmacists' Association; 1999.
23. Dionex. Technical note 10: determination of transition metals by ion chromatography. Sunnyvale: Thermo Fisher Scientific. Available from .
24. Han J, Beeton A, Long PF, Wong I, Tuleu C. Physical and microbiological stability of an extemporaneous tacrolimus suspension for paediatric use. J Clin Pharm Ther 2006; 31: 167-72.
25. Legssyer R, Geisser P, McArdle H, Crichton RR, Ward RJ. Comparison of injectable iron complexes in their ability to iron load tissues and to induce oxidative stress. Biometals 2003; 16: 425-33.
26. International Conference on Harmonisation Steering Committee. ICH harmonised tripartite guideline. Validation of analytical procedures: text and methodology Q2 (R1). Geneva: International Conference on Harmonisation; 2005.
27. Trissel LA. Avoiding common flaws in stability and compatibility studies of injectable drugs. Am J Hosp Pharm 1983; 40: 1159-61.
28. Patel RP, Narkowicz C, Jacobson GA. Investigation of the effect of heating on the chemistry and antifactor Xa activity of enoxaparin. J Pharm Sci 2009; 98: 1700-11.
29. Yang Y, Shah RB, Faustino PJ, Raw A, Yu LX, Khan MA. Thermodynamic stability assessment of a colloidal iron drug product: sodium ferric gluconate. J Pharm Sci 2010; 99: 142-53.